See more : Telenet Group Holding NV (TLGHF) Income Statement Analysis – Financial Results
Complete financial analysis of K Pharma,Inc. (4896.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of K Pharma,Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Phoenix Spree Deutschland Limited (PSDL.L) Income Statement Analysis – Financial Results
- Escorts Kubota Limited (ESCORTS.NS) Income Statement Analysis – Financial Results
- Kismet Acquisition Two Corp. (KAIIW) Income Statement Analysis – Financial Results
- Chain Chon Industrial Co., Ltd. (5014.TWO) Income Statement Analysis – Financial Results
- Dainichiseika Color & Chemicals Mfg. Co., Ltd. (DCHCF) Income Statement Analysis – Financial Results
K Pharma,Inc. (4896.T)
About K Pharma,Inc.
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 1.00B | 0.00 | 0.00 |
| Cost of Revenue | 90.00M | 0.00 | 6.80M |
| Gross Profit | 910.00M | 0.00 | -6.80M |
| Gross Profit Ratio | 91.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 163.97M | 134.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | -1.00K | 169.38M | 67.97M |
| Other Expenses | 543.94M | -45.00K | -4.00K |
| Operating Expenses | 543.94M | 353.77M | 219.49M |
| Cost & Expenses | 633.94M | 353.77M | 219.49M |
| Interest Income | 16.00K | 7.00K | 1.00K |
| Interest Expense | 11.85M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.00K | 31.29M | 6.80M |
| EBITDA | 366.06M | -322.48M | -222.32M |
| EBITDA Ratio | 36.61% | 0.00% | 0.00% |
| Operating Income | 366.06M | -353.77M | -219.49M |
| Operating Income Ratio | 36.61% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.98M | -36.75M | -9.63M |
| Income Before Tax | 301.08M | -390.53M | -229.12M |
| Income Before Tax Ratio | 30.11% | 0.00% | 0.00% |
| Income Tax Expense | 40.75M | 1.90M | -400.00K |
| Net Income | 260.33M | -392.43M | -228.72M |
| Net Income Ratio | 26.03% | 0.00% | 0.00% |
| EPS | 22.43 | -42.06 | -19.79 |
| EPS Diluted | 22.43 | -42.06 | -19.79 |
| Weighted Avg Shares Out | 11.60M | 9.33M | 11.56M |
| Weighted Avg Shares Out (Dil) | 11.60M | 9.33M | 11.56M |
Source: https://incomestatements.info
Category: Stock Reports